Myocardial work in chronic kidney disease: insights from the CPH-CKD ECHO Study

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningfagfællebedømt

Background
Myocardial work is a novel echocardiographic measure that offers detailed insights into cardiac mechanics. We sought to characterize cardiac function by myocardial work in patients with chronic kidney disease (CKD).

Methods
We prospectively enrolled 757 patients with non-dialysis-dependent CKD and 174 age- and sex-matched controls. Echocardiographic pressure-strain loop analysis was performed to acquire the global work index (GWI). Linear regressions were performed to investigate the association between estimated glomerular filtration rate (eGFR) and urine albumin-creatinine ratio (UACR) to GWI.

Results
Patients with CKD had a mean age of 57 years, 61% were men, and median eGFR was 42 mL/min/1.73 m2. Overall, no difference in GWI was observed between patients and controls (1879 vs. 1943 mmHg%, p = 0.06). However, a stepwise decline in GWI was observed for controls vs. patients with CKD without left ventricular hypertrophy vs. patients with CKD and left ventricular hypertrophy (GWI, 1943 vs. 1887 vs. 1789 mmHg%; p for trend = 0.030). In patients with CKD, eGFR was not associated with GWI by linear regression. However, diabetes modified this association (p for interaction = 0.007), such that per 10 mL/min/1.73 m2 decrease in eGFR, GWI decreased by 22 (9–35) mmHg% (p = 0.001) after multivariable adjustments in patients without diabetes, but with no association between eGFR and GWI in patients with diabetes. No association was observed between UACR and GWI.

Conclusion
Patients with CKD and left ventricular hypertrophy exhibited lower myocardial work compared to matched controls. Furthermore, decreasing eGFR was associated with decreasing myocardial work only in patients without diabetes. No association to UACR was observed.
OriginalsprogEngelsk
TidsskriftClinical Research in Cardiology
ISSN1861-0684
DOI
StatusE-pub ahead of print - 2024

Bibliografisk note

Funding Information:
Open access funding provided by Copenhagen University. The study received funding from the Capital Region of Denmark (Region Hovedstaden).

Funding Information:
D.H.: Steering Committee member of the Boehringer Ingelheim financed SHARP3 trial. Advisory Board: GSK. Lecture fee: Astra Zeneca and UCB Nordic. E.L.F.B.: Received non-related research grants from AstraZeneca. T.B-S.: Steering Committee member of the Amgen financed GALACTIC-HF trial. Primary investigator of the Sanofi Pasteur financed \u201CNUDGE-FLU\u201D trial. Primary investigator of the Sanofi Pasteur financed \u201CDANFLU-1\u201D trial. Primary investigator of the Sanofi Pasteur financed \u201CDANFLU-2\u201D trial. Steering Committee member of \u201CLUX-Dx TRENDS Evaluates Diagnostics Sensors in Heart Failure Patients Receiving Boston Scientific\u2019s Investigational ICM System\u201D trial. Steering Committee member of the Boehringer Ingelheim financed SHARP3 trial. Advisory Board: Sanofi Pasteur, Amgen, and GSK. Speaker Honorarium: Novartis, Sanofi Pasteur, GE Healthcare, and GSK. Research grants: GE Healthcare, AstraZeneca, Novo Nordisk and Sanofi Pasteur. The other authors declare no conflict of interest.

Publisher Copyright:
© The Author(s) 2024.

ID: 393057699